Alliant Insurance Services Adds Strength to Louisiana Brokerage Team, Hires Buzz Mansfield
Mansfield to provide tailored property and casualty insurance solutions to growing Southeast client base IRVINE, Calif.–(BUSINESS WIRE)–#AlliantInsurance—Alliant... Read more.
Good Time Brewing Company Expands With Direct-to-Consumer Shipping in Time for Dry January –Storied West Village Bar Owner Embraces N/A Wave–
NEW YORK–(BUSINESS WIRE)–#NYC–Good Time Brewing Company, founded by bar industry luminary Michael “Mikey” McFerran, proudly announces the launch... Read more.
Upfort Named a Winner of the 2023 BIG Awards for Business and Pan Finance Awards 2023
Upfort recognized as ‘Startup of the Year’ by Business Intelligence Group and ‘Cyber Insurance Provider of the Year – USA 2023’ by Pan Finance SAN... Read more.
Middleburg Communities to Develop Dynamic Build-to-Rent Community in Wilmington, North Carolina
280-unit development to offer a mix of cottages, duplexes and townhomes and feature pocket parks, shared greenspace and streetscapes VIENNA, Va.–(BUSINESS... Read more.
ENYO Pharma Announces a €39 Million Series C Financing and FDA Clearance to Advance Vonafexor in a Phase 2 Clinical Trial for Patients With Alport Syndrome
The Company will initiate a Phase 2 clinical study of Vonafexor in Alport Syndrome – called “ALPESTRIA-1” – in the first half of 2024. Series C proceeds... Read more.
EnerSys Announces Proposed Offering of Senior Notes
READING, Pa.–(BUSINESS WIRE)–EnerSys (NYSE: ENS) (“EnerSys” or the “Company”) announced today that it intends to offer, subject to market and... Read more.
Cathedra Bitcoin Provides Operations Update
TORONTO–(BUSINESS WIRE)–$CBIT #Bitcoin–(Block Height: 824,060) – Cathedra Bitcoin Inc. (TSX-V: CBIT; OTCQB: CBTTF) (“Cathedra” or the “Company”),... Read more.
ReCode Therapeutics Doses First Patient in Phase 1 Clinical Study of Novel mRNA-based Therapy for the Treatment of Primary Ciliary Dyskinesia
Phase 1 study aims to evaluate safety and tolerability of a single ascending dose of RCT1100 in patients with PCD caused by mutations in the DNAI1 gene RCT1100 is... Read more.
Summit Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
MENLO PARK, Calif.–(BUSINESS WIRE)–$SMMT–Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced... Read more.
Areteia Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024
CHAPEL HILL, N.C.–(BUSINESS WIRE)–Areteia Therapeutics, Inc. (“Areteia”) announced today that the company will present at the 42nd Annual J.P. Morgan... Read more.